F10 and interstitial lung disease: All 3 FXa inhibitors were associated with a significantly higher risk of incident ILD (apixaban: 0.35 vs 0.17 per 100 patient-years [HR, 1.72; 95% CI, 1.27-2.31]; edoxaban: 0.37 vs 0.17 per 100 patient-years [HR, 1.60; 95% CI, 1.12-2.27]; rivaroxaban: 0.27 vs 0.17 per 100 patient-years [HR, 1.48; 95% CI, 1.16-1.88]; P = .75) compared with warfarin after PSSW (eFigure 2 in the Supplement).